but not all hallucinogens (2, 3) and is the target of a number of commonly prescribed therapeutic agents including atypical antipsychotics, antidepressants, and anxiolytics (4, 5). As with other G protein-coupled receptors (GPCRs) (6 -8), elucidating the regulatory mechanisms for 5-HT 2A receptor signaling and trafficking provides important insights into the therapeutic mechanisms of drugs that target the 5-HT 2A receptor and has implications for the rational design of novel medications (5, 6).
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The 5-HT 2A receptor, the most abundant serotonin receptor in the cerebral cortex, is enriched in dendritic shafts and, to a lesser extent, asymmetric synapses and dendritic spines of pyramidal neurons primarily from Layers IV and V (9 -13). The last four amino acids (VSCV) of the carboxyl terminus of the 5-HT 2A receptor constitute a canonical Type I PDZ-binding domain (X-Ser/Thr-X-⌽) (14) . The PDZ-binding domain is located at the carboxyl terminus of a variety of proteins including many GPCRs and is known to associate with PSD-95/Discslarge/ZO-1 (PDZ) domain-containing proteins of which postsynaptic density 95 (PSD-95, also known as synapse-associated protein 90 or SAP-90, is a prototypic member (15, 16) . These multi-domain molecules not only target and provide scaffolds for protein-protein interactions but can also modulate the functions of ion channels and receptors with which they associate (16 -20) . The disruption of the association between PDZ proteins and their targets contributes to the pathogenesis of a number of human diseases (16, 21, 22) , most probably because of the failure of PDZ proteins to appropriately target and modulate the actions of the associated proteins. Na ϩ /H ϩ exchanger regulatory factor (NHE-RF) was the first PDZ domain-containing protein that was reported to modulate the function of a GPCR (e.g. the ␤ 2 -adrenergic receptor (␤ 2 -AR)) (23) . Subsequently, PSD-95 was found to associate with and inhibit the internalization of ␤ 1 -ARs and to facilitate the interaction between the ␤ 1 -AR and the N-methyl-D-aspartate ionotropic glutamate receptor (24, 25) . Among the 5-HT 2 class of serotonin receptors, a multi-PDZ domain-containing protein, MUPP1, associates with 5-HT 2C receptors in vitro and in vivo (26) . MUPP1 has also been predicted to interact with both the 5-HT 2A and the 5-HT 2B receptor based on its ability to bind to purified COOH-terminal fusion proteins of both receptors in vitro (26) . Furthermore, a proteomic approach has recently identified PSD-95 as a component of a multi-protein complex that associates with the 5-HT 2C receptor in vivo (27) . PSD-95, similar to the 5-HT 2A receptor, is enriched in asymmetric synapses and dendritic spines of cortical pyramidal neurons (28, 29) and is thus predicted to interact with 5-HT 2A receptors. The functional significance of any association between PDZ proteins and 5-HT receptors is unknown because none has been previously reported.
Therefore, we set out to investigate whether PSD-95 interacts with and regulates 5-HT 2A receptors. A combination of biochemical and immunocytochemical approaches demonstrated that PSD-95 directly interacts with the 5-HT 2A receptor in vitro. We also discovered that PSD-95 enhanced 5-HT 2A receptor-mediated signaling, inhibited agonist-induced 5-HT 2A receptor internalization, and promoted 5-HT 2A receptor clustering on the plasma membrane. Thus, this work demonstrates a novel role for PSD-95 in modulating the activity of a GPCR. These findings have important implications for elucidating the roles of PDZ domain-containing proteins in regulating the functions of the 5-HT family of receptors and possibly other GPCRs.
EXPERIMENTAL PROCEDURES
cDNA Constructs and Reagents-The construct coding for FLAGtagged wild type (WT) rat 5-HT 2A receptor (FLAG-5-HT 2A ) was modified from a similar construct that has been described previously (30) by adding an amino-terminal cleavable signal peptide sequence [MKTI-IALSYIFCLVFA (31)] derived from influenza hemagglutinin. The addition of such a signal sequence has been shown to increase the expression of GPCRs (31) . FLAG-5-HT 2A ⌬469 -471 was constructed by using FLAG-5-HT 2A as the template and by introducing a premature stop codon at residue 469, the third to the last amino acid of the carboxyl terminus, using site-directed mutagenesis (5Ј-primer: 5Ј-CGTGAAT-GAAAAGGTTTGATGTGTGTGATCTAGAGGGCCC-3Ј, and 3Ј-primer: 5Ј-GGGCCCTCTAGATCACACACATCAAACCTTTTCATTCACG)-3Ј (QuikChange). Deletion of amino acid residues 469 -471 effectively ablates the PDZ-binding domain of the 5-HT 2A receptor. PSD-95-GFP (a generous gift from D. Bredt) has been described elsewhere (32) . The EGFP-C2 vector (Clontech, Palo Alto, CA) contained the GFP coding sequence. The constitutively active G␣ q mutant (Q229L) (a generous gift from D. Siderovski) has been described elsewhere (33) . All of the constructs containing inserts in the appropriate orientation were verified by automated sequencing (Cleveland Genomics, Cleveland, OH).
5-Hydroxytryptamine creatinine sulfate (5-HT), quipazine, clozapine, chlorpromazine, (Ϯ)-2,5-dimethoxy-4-iodoamphetamine hydrochloride, CHAPS, and sodium orthovanadate were acquired from Sigma. [ 3 H]Ketanserin and myo-[ 3 H]inositol were purchased from PerkinElmer Life Sciences.
Transfection of HEK-293 Cells-Human embryonic kidney 293 (HEK-293) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, penicillin (100 units/ml), and streptomycin (100 mg/ ml) (Invitrogen) at 37°C and 5% CO 2 . Transient transfection with FuGENE 6 (Roche Applied Sciences) using a FuGENE 6 to DNA ratio of 5:1 was performed according to the manufacturer's recommendations. A total of 6 g of DNA was used in each co-transfection, 4 g of which were vector, 5-HT 2A receptor, or mutant 5-HT 2A receptor DNA and 2 g of which were DNA encoding either PSD-95-GFP or GFP.
Co-immunoprecipitation and Immunoblot-At 24 h after co-transfection, HEK-293 cells were split into 6-well plates and cultured first in DMEM supplemented with 5% dialyzed FBS for 24 h and then in DMEM without serum for an additional 24 h. Cells were washed at 4°C twice with PBS and once with Buffer A (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 10 mM Na 4 P 2 O 7 , and 2 mM sodium orthovanadate, pH 7.5). Cells were lysed by incubation on a rocker platform at 4°C for 15 min in Buffer A containing 1.5% CHAPS and EDTA-free Complete protease inhibitor tablets (Roche Applied Sciences). A portion of the cell lysates was saved for subsequent determination of total protein expression levels, and the remainder was incubated with Sepharose beads conjugated to a monoclonal FLAG antibody (Sigma) at 4°C for 2 h. The beads were washed at 4°C for three times in Buffer B (50 mM HEPES, 150 mM NaCl, 0.3% Triton X-100, and 10% glycerol, pH 7.5). Immunoprecipitated proteins were then eluted from the beads by resuspension in 2ϫ SDS sample buffer. Samples were heated for 5 min at 67°C, and proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Immunoblotting was performed according to standard Table I. methods (30, 34) . A polyclonal GFP antibody (1:2000) (Abcam, Cambridge, United Kingdom) was used to detect PSD-95-GFP or GFP. A rabbit polyclonal FLAG antibody (1:1500) was used to detect FLAGtagged WT and mutant 5-HT 2A receptors. The constitutively active G␣ q mutant and the endogenous WT G␣ q in cell lysates were detected by a rabbit polyclonal G␣ q antibody (1:2000) (Santa Cruz Biotechnology, Santa Cruz, CA). The levels of PSD-95-GFP expression from immunoprecipitates and cell lysates were quantified using a chemiluminescence imaging system (Kodak Scientific Imaging System, Eastman Kodak Co.). The levels of PSD-95-GFP expression from immunoprecipitates were subsequently normalized to corresponding levels in cell lysates.
Agonist-mediated Internalization-At 24 h after co-transfection, HEK-293 cells were split into 24-well plates containing poly-L-lysinecoated coverslips and maintained in DMEM supplemented with 5% dialyzed FBS for 24 h and then in DMEM without serum for an additional 24 h. Cells were treated for 15 min at 37°C with 5-HT at a final concentration of 10 M. Treatment was terminated by placing cells at 4°C, removing media, and fixing with 4% paraformaldehyde. Immunocytochemistry was performed, confocal images were acquired (see "Immunocytochemistry, Confocal Microscopy, and Image Quantification"), and internalization was quantified using the MetaView imaging software (Universal Imaging, Downingtown, PA).
Phosphoinositide Hydrolysis, Radioligand Binding, and Desensitization Assays-Phosphoinositide (PI) hydrolysis and saturation radioligand binding assays were performed on cells from the same transfection. At 24 h following transfection, HEK-293 cells were either 1) split into poly-L-lysine-coated 24-well plates and maintained in DMEM supplemented with 5% dialyzed FBS for 24 h and then in serum-free and inositol-free DMEM for an additional 24 h before performing PI hydrolysis assay or 2) kept in DMEM supplemented with 5% dialyzed FBS for 24 h and then in serum-free DMEM for additional 24 h before harvesting cell membranes for binding assay. As described previously, agonist efficacy (E max ) and potency (EC 50 ) were determined from dose-response PI hydrolysis assays and kinetic binding parameters (B max and K d ) were determined from saturation binding assays with [ 3 H]ketanserin (35) . The resulting E max values were then normalized to B max values with results replicated in at least three separate experiments. PI hydrolysis data were analyzed by nonlinear regression using the GraphPad Prism software (San Diego, CA), and saturation binding data were analyzed using GraphPad Prism or the weighted nonlinear least-squares curvefitting program LIGAND (36) . Agonist-dependent desensitization of 5-HT 2A receptor-mediated accumulation of inositol phosphate (IP) was performed as described previously (34, 35) .
Immunocytochemistry, Confocal Microscopy, and Image Quantification-Dual-labeling immunocytochemistry was performed essentially as described previously (30) . HEK-293 cells were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 at 4°C, blocked with 5% milk, incubated with primary antibodies overnight at 4°C and then with secondary antibodies, conjugated to the appropriate Alexa Fluor dyes (Molecular Probes, Eugene, OR), and finally mounted on glass slides. FLAG-tagged constructs were visualized using a monoclonal FLAG antibody (1:1500) (Stratagene). GFP-tagged constructs were visualized with a rabbit polyclonal GFP antibody (1:2000) (Abcam, Cambridge, United Kingdom). Images of cells were acquired digitally using a Zeiss 410 confocal microscope (Oberkochen, Germany) without saturation of pixel intensities and were subsequently analyzed using MetaView (Universal Imaging) as previously detailed (30, 34, 35, 37, 38) . For each cell in which 5-HT 2A receptor internalization was quantified, two measurements were made: 1) total cellular immunofluorescence and 2) intracellular immunofluorescence. The extent of 5-HT 2A receptor internalization was then defined as the percentage of the total 5-HT 2A receptor immunofluorescence, which was intracellular. For each sample group, at least 50 cells were quantified in a blinded fashion. In prior studies (30, 37) , we have demonstrated that this method provides quantitative estimates of internalization that are essentially equivalent to results obtained by biochemical techniques such as surface biotinylation.
Statistical Analysis-Data from co-immunoprecipitation and internalization studies were analyzed using the unpaired Student's t test For these experiments, a constitutively active form of G␣ q (Q229L or G␣ q * ) was co-transfected with either GFP or PSD-95-GFP. A, representative immunoblot of total G␣ q from all of the sample groups (in duplicate). B, quantification of the net pixel intensities of bands from three independent experiments showed equal levels of total G␣ q expression in the presence or absence of PSD-95, both of which were significantly higher than that from nontransfected cells because of the overexpression of G␣ q (Fig. 1A, lanes 9 and 10) , indicating that 5-HT 2A receptors and PSD-95 directly interact in vitro (see Fig. 1E for quantification).
To To further establish the specificity of the interaction between the 5-HT 2A receptor and PSD-95, we performed a number of controls. First, we showed that cells co-transfected with PSD-95-GFP and an empty vector (Fig. 1, A, lanes 7 and 8, and E) yielded minimal pull-down of PSD-95. Second, no PSD-95 was immunoprecipitated from nontransfected cells (Fig. 1A, lanes 1  and 2) or from cells co-expressing 5-HT 2A receptors (WT or mutant) and GFP (Fig. 1A, lane 3-6 ). These findings demonstrated the specificity of PSD-95 association with 5-HT 2A receptors. Finally, the significantly higher levels of PSD-95 that co-immunoprecipitated with WT 5-HT 2A receptors (Fig. 1A , lanes 9 and 10) resulted neither from variations in the expression of WT or mutant 5-HT 2A receptors in immunoprecipitates (Fig. 1B, lanes 3-6 and lanes 9 -12) or in cell lysates (Fig. 1D,  lanes 3-6 and lanes 9 -12) nor from variations in PSD-95 expression (Fig. 1C, lanes 7-12; receptor is a G q -coupled receptor that activates phospholipase C (PLC) (39), we measured inositol phosphate (IP) accumulation resulting from 5-HT 2A receptor-mediated PI hydrolysis (Fig. 2) and determined in parallel the expression of 5-HT 2A receptors by immunoblot analysis (Fig. 1, B and D) and saturation binding assays. We then normalized the functional activity of the 5-HT 2A receptor (i.e. IP accumulation) to the expression level of the 5-HT 2A receptor (i.e. B max ), thus accounting for minor variations in 5-HT 2A receptor activation that might have resulted from variations in receptor expression. Assays were also performed under the conditions of minimal receptor reserve (35) .
PSD-95 significantly enhanced WT 5-HT 2A receptor-mediated signaling when compared with the base line (i.e. 5-HT 2A receptors co-transfected with GFP) (Fig. 2 , WT 5-HT 2A ϩ PSD-95 versus WT 5-HT 2A ϩ GFP) ( Table I ). The augmentation of signaling by PSD-95 was not seen when PSD-95 was cotransfected with the 5-HT 2A ⌬469 -471 mutant (Fig. 2 , 5-HT 2A ⌬469 -471 ϩ PSD-95) ( Table I) . Blocking the direct physical interaction between PSD-95 and 5-HT 2A receptors thus inhibited the ability of PSD-95 to augment 5-HT 2A signaling. Interestingly, PSD-95 did not alter agonist potency (Table  I) , and there was no apparent alteration in the constitutive activity of any of the receptor constructs (measured as detailed by Shapiro et al. (40) ; data not shown). These results indicate that PSD-95 via a direct physical interaction with 5-HT 2A receptors augments 5-HT 2A receptor-mediated signaling.
To investigate the possibility that PSD-95 augments the PLC signaling pathway by associating with downstream effectors (i.e. G␣ q and PLC), we examined whether PSD-95 increased IP accumulation in cells expressing a constitutively active form of G␣ q (Q229L and G␣ q * ), which activates PLC directly (33) . In the absence of 5-HT 2A receptor expression, PSD-95 neither altered the G␣ q * -stimulated IP accumulation when compared with GFP alone (Fig. 3C) nor affected the relative expression of G␣ q * (Fig. 3, A and B) . These findings strongly suggest that PSD-95 enhances intracellular signaling at the level of receptor-effector coupling and not via a receptor-independent augmentation of G␣ q signaling. 2A Receptors-To determine the potential cellular mechanisms subserving the PSD-95-mediated augmentation of 5-HT 2A receptor signaling, we examined whether PSD-95 alters the time course of 5-HT 2A receptor desensitization. We have previously reported that exposure to agonists inhibits the activation of the 5-HT 2A receptor by the process of desensitization whereby receptors on the cell surface no longer respond to agonists and fail to efficiently signal downstream pathways (41) . PSD-95 did not attenuate agonist-dependent 5-HT 2A receptor desensitization when compared with the base line (Fig.  4 , WT 5-HT 2A ϩ PSD-95 versus WT 5-HT 2A ϩ GFP). Likewise, disrupting the association between PSD-95 and 5-HT 2A receptors had no effect on agonist-dependent desensitization of 5-HT 2A receptors (Fig. 4, 5-HT 2A ⌬469 -471 ϩ PSD-95) . Hence, PSD-95 does not enhance 5-HT 2A receptor signaling by attenuating the desensitization of 5-HT 2A receptors. 2A Receptors-We next investigated whether PSD-95 affects the targeting and trafficking of 5-HT 2A receptors. We have previously demonstrated that acute exposure to agonists facilitates the redistribution of 5-HT 2A receptors from the plasma membrane to the intracellular pool via receptor internalization (30) . As expected, 5-HT induced the rapid internalization of WT 5-HT 2A receptors (Fig. 5, A-C versus D-F; see Fig. 7 for quantification) . Interestingly, PSD-95 significantly inhibited the agonist-induced 5-HT 2A receptor internalization (Figs. 5, G-I versus J-L, and 7) and promoted the co-clustering (i.e. formation of puncta containing both proteins) of 5-HT 2A receptors with PSD-95 on the cell surface (Figs. 5, G-I (cross-section view) , and 8, A-C (top view)).
PSD-95 Does Not Affect the Agonist-dependent Desensitization of 5-HT

PSD-95 Inhibits the Agonist-induced Internalization and Promotes the Cell Surface Clustering of 5-HT
As an essential control, we found that disrupting the PDZbinding domain of the 5-HT 2A receptor blocked the ability of PSD-95 to inhibit 5-HT 2A receptor internalization (Figs. 6, A-C  versus D-F, and 7) . Furthermore, disrupting the PDZ-binding domain attenuated 5-HT 2A receptor clustering on the cell surface (Figs. 6, A-C (cross-section view), and 8, D-F (top view)) . Interestingly, whereas WT 5-HT 2A receptors appeared to co-cluster with the membrane-bound PSD-95, mutant 5-HT 2A ⌬469 -471 receptors did not facilitate the formation of PSD-95-immunoreactive puncta on the cell surface (Figs. 5, 
G-I versus J-L, and 6, A-C versus D-F).
Taken together, these findings suggest that PSD-95 augments 5-HT 2A receptor-mediated signaling at least in part by inhibiting the internalization and promoting the cell surface clustering of 5-HT 2A receptors.
DISCUSSION
The major findings of this work are that PSD-95 directly interacts with 5-HT 2A receptors in vitro, thereby augmenting 5-HT 2A receptor signaling, inhibiting the agonist-dependent internalization, and promoting the cell surface clustering of the 5-HT 2A receptor. PSD-95 was recently reported to be among the several PDZ domain-containing proteins that physically interact with the closely related 5-HT 2C receptor in vivo (27) , although the physiological significance of the interaction between 5-HT receptors and PDZ domain-containing proteins is largely unknown. Although there is precedence for GPCR signaling being enhanced by another PDZ domain-containing protein (23), this is the first report that PSD-95, a prototypic PDZ domain-containing protein and a major synaptic protein, enhances the signaling of any GPCR. Taken together, these results imply that interactions with PDZ domain-containing proteins may represent a generalized mechanism for modulating GPCR-mediated signal transduction.
PSD-95 is known to associate with a variety of target proteins, including the NMDA receptor (14) , ␤ 1 -AR (24), neuroligin (42) , cysteine-rich interactor of PDZ three (43) , and citron (44) . Superficially, the association of PSD-95 with the 5-HT 2A receptor is reminiscent of PSD-95 interactions with the ␤ 1 -AR. Most notably, the extreme carboxyl terminus of the ␤ 1 -AR (Ser-LysVal) and the 5-HT 2A receptor (SCV) shares the same Type I PDZ-binding motif (X-Ser/Thr-X-⌽) and could conceivably interact with the same PDZ domain on PSD-95. Moreover, PSD-95 inhibits the agonist-induced internalization of both the ␤ 1 -AR (24) and the 5-HT 2A receptor. On the other hand, we have discovered significant differences. In particular, PSD-95 augments 5-HT 2A receptor signaling but has no effect on ␤ 1 -AR signaling (24) .
The precise mechanism by which PSD-95 augments 5-HT 2A -mediated signaling is unknown but is probably because of a direct physical interaction. Thus, PSD-95 potentiates the signaling of wild-type 5-HT 2A receptors but not mutant 5-HT 2A receptors lacking the PDZ-binding domain. Additionally, PSD-95 does not augment basal (constitutive) 5-HT 2A receptor signaling, alter agonist potency, perturb the kinetics of agonistdependent 5-HT 2A receptor desensitization, or affect the ability of a constitutively active G␣ q (G␣ q -Q229L) to activate PLC. Taken together, these results are consistent with the notion that PSD-95 augments receptor-effector signaling via a direct physical interaction between 5-HT 2A receptors and PSD-95. Based on the present finding that PSD-95 augments 5-HT 2A receptor signaling, it is reasonable to speculate that PSD-95 provides scaffolding for G q and PLC, thereby facilitating the interaction between the 5-HT 2A receptor and these downstream signaling molecules. Studies to test this hypothesis are in progress.
We have also found that PSD-95 inhibits the agonist-induced 5-HT 2A receptor internalization. A possible mechanism by which PSD-95 inhibits 5-HT 2A receptor internalization is that PSD-95 recruits and anchors multiple proteins including the 5-HT 2A receptor to the plasma membrane, assembling a complex that in turn prevents the internalization of component molecules. For example, PSD-95 is known to assemble ␤ 1 -AR and NMDA receptor in the same complex (24) . Consistent with reports of cell surface co-localization between MUPP1 and 5-HT 2C receptor (26) and between PSD-95 and ␤ 1 -AR (24), 5-HT 2A receptors also co-cluster with PSD-95 as the distribu- It is worth noting that PSD-95 inhibits the internalization of the 5-HT 2A receptor but does not affect the agonist-dependent desensitization, considering that these regulatory mechanisms for GPCRs (i.e. internalization, desensitization, and resensitization) are frequently linked. We have previously demonstrated that both the desensitization and the resensitization of the 5-HT 2A receptor are not affected by various well characterized inhibitors of clathrin-mediated endocytosis in HEK-293 cells (35, 41) . In addition, it is unlikely that the PDZ-binding domain is involved in agonist-dependent GPCR desensitization because disruption of the PDZ-binding domain does not prevent 5-HT 2C receptors from undergoing desensitization (45) .
Another potential mechanism for PSD-95-mediated inhibition of 5-HT 2A receptor internalization could involve competition for the same binding motif with regulatory molecules that facilitate 5-HT 2A receptor internalization. Studies of PSD-95/ Kir2.3 and NHE-RF/␤ 2 -AR associations suggest that phosphorylation of the serine or threonine residue at the Ϫ2 position of the canonical PDZ-binding domain by G protein-coupled receptor kinases (GRK) may be the regulatory mechanism with which PSD-95 competes (23, 46 -48) . One such counter-regulatory molecule is GRK5. Upon agonist stimulation, GRK5 phosphorylates the serine residue of the PDZ-binding domain of both ␤ 1 -AR and ␤ 2 -AR, thereby diminishing receptor association with PDZ proteins (PSD-95 and NHE-RF, respectively) and facilitating receptor internalization (47, 48) . Neither GRK5 nor GRK2 is likely to compete with PSD-95 for binding sites on the 5-HT 2A receptor, however, since we have demonstrated that 5-HT 2A receptors are regulated by GRK2-and GRK5-independent processes (35) .
Because PSD-95 becomes membrane-bound following palmitoylation (49), the preferential localization of PSD-95 to the plasma membrane makes it unlikely that PSD-95 could enhance 5-HT 2A receptor recycling (50), a possibility that might otherwise confound the interpretation of the present observation. It would be interesting to examine in the future whether an alternatively spliced isoform of PSD-95 (PSD-95␤) that lacks palmitoylation sites in the amino terminus and is not membranebound (51) could inhibit 5-HT 2A receptor internalization.
In summary, we have discovered a novel role for PSD-95 for regulating the activity of GPCRs. PSD-95 augments 5-HT 2A receptor-mediated signaling in a way that requires a direct physical interaction between 5-HT 2A receptors and PSD-95. This study demonstrates that PSD-95, a component of the neuronal protein sorting apparatus, regulates 5-HT 2A receptor signaling at least in part by anchoring 5-HT 2A receptors to the cell surface in clusters that are not easily internalized by agonists and possibly by facilitating 5-HT 2A receptor interaction with downstream signaling molecules. Because 5-HT 2A receptors are responsible for the actions of atypical antipsychotic drugs (4, 5, 37, 52) and most (1, 5) but not all (2, 3) hallucinogens, elucidating the cellular machinery responsible for targeting and regulating 5-HT 2A receptors will enhance our understanding of how diverse classes of drugs exert their profound effects on human perception, emotion, and cognition.
